Martin Schoen, MD
Hematology & Oncology · Saint Louis, MONPI 1568511467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,500 of the $2,042 with a category attached, or 73.5%. Pfizer accounts for 87.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,500 and has fallen 90.1% since, to $149 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 9 payments — averaging $226.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Incyte Corporation$100
- Astellas Pharma US Inc$95
- AbbVie$37
- Pharmacyclics LLC, An Abbvie Company$22
- Amgen$11
Across 7 payments — averaging $15,353 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$107K
What the payments were for
- Speaking & faculty fees$1,50073%
- Food & beverage$34717%
- Education$19510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $1,776 |
| Incyte Corporation | 1 | $100 |
| Astellas Pharma US Inc | 1 | $95 |
| AbbVie | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$1,500
How this compares
$2,042 in reported general payments places this provider in the 50th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Saint Louis
- Mark FeslerSaint Louis$870K
- Jonathan MizrahiSaint Louis$188K
- Geoffrey UySaint Louis$28K
- Deepthi BusayavalasaSaint Louis$22K
- Jason LiSaint Louis$17K
- John FinnieSaint Louis$14K
- Atif ShafqatSaint Louis$7K
- Shabbir SafdarSaint Louis$7K
- Bryan FallerSaint Louis$6K
- Heide RodgersSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.